ACC pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
20 of 25 arms with a reported figure. Choose arms to narrow the chart.
| Arm | Reported safety |
|---|---|
| Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source) | n/r |
| Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source) | n/r |
| Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source) | grade 3 treatment-related adverse events: 79.2%, ASCO 2026treatment-related discontinuation: 2.1%, ASCO 2026dose reduction: 45.8%, ASCO 2026 |
| RGT-61159 at or below RP2D (mixed doses) | n/r |
| REM-422 24 mg | n/r |
| REM-422 12 to 48 mg | n/r |
| REM-422 24 mg | treatment-related epistaxis (all grade 1 or 2): 60%, cutoff 01.07.2026treatment-related fatigue (all grade 1 or 2): 60%, cutoff 01.07.2026 |
| Osugacestat (AL101, BMS-906024) 4 mg | patients with serious adverse events: 23 patients (of 45), final |
| Osugacestat (AL101, BMS-906024) 6 mg | patients with serious adverse events: 26 patients (of 42), final |
| Lenvatinib (off Label) 24 mg | grade 3 or 4 hypertension: 28.1%, primary analysisdiscontinued for drug-related issues: 18 patients (of 32), primary analysis |
| Lenvatinib (off Label) 24 mg | grade 3 or higher treatment-related adverse events: 50%, primary analysis |
| Lenvatinib (off Label) not stated in source | grade 3 or higher toxicity: 71%, ASCO 2023 (search record) |
| Axitinib (off Label) 5 mg | n/r |
| Axitinib (off Label) none | n/r |
| Axitinib (off Label) axitinib 5 mg twice daily + avelumab | serious treatment-related adverse events: 29%, primary analysis |
| Axitinib (off Label) as above | n/r |
| Axitinib (off Label) as above | n/r |
| Rivoceranib 700 mg | grade 3 or higher treatment-related adverse events: 70%, primary analysisdiscontinued for toxicity: 20%, primary analysis |
| Amivantamab not stated in source | patients with serious adverse events: 7 patients (of 21), results posted |
| Regorafenib (off Label) not stated in source | patients with serious adverse events: 14 patients (of 38), results posted |
A count stays a count. This page does not turn a count into a percent.
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.